Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Erbitux Ultimatum: Company Wants Control Of FDA Negotiations

Executive Summary

Bristol-Myers Squibb wants responsibility for the regulatory and clinical future of Erbitux under a proposed restructuring of the company's relationship with ImClone

You may also be interested in...



Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions

Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies

Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions

Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies

Bristol Erbitux Decision Will Follow Feb. 26 FDA Meeting

Bristol-Myers Squibb will decide whether to proceed with the Erbitux collaboration with ImClone after a Feb. 26 meeting with FDA

Related Content

UsernamePublicRestriction

Register

PS039276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel